Birgegård G - Search Results

1

Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial.

Svanberg A, Birgegård G, Ohrn K. Svanberg A, et al. Among authors: birgegard g. Support Care Cancer. 2007 Oct;15(10):1155-61. doi: 10.1007/s00520-007-0245-8. Epub 2007 Mar 29. Support Care Cancer. 2007. PMID: 17393189 Clinical Trial.

2

Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.

Svanberg A, Birgegård G. Svanberg A, et al. Among authors: birgegard g. Oncology. 2015;89(1):31-6. doi: 10.1159/000371523. Epub 2015 Feb 4. Oncology. 2015. PMID: 25659986 Clinical Trial.

3

Caphosol(®) mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study.

Svanberg A, Öhrn K, Birgegård G. Svanberg A, et al. Among authors: birgegard g. Eur J Oncol Nurs. 2015 Feb;19(1):50-3. doi: 10.1016/j.ejon.2014.07.011. Epub 2014 Sep 13. Eur J Oncol Nurs. 2015. PMID: 25224595 Clinical Trial.

4

The effect of cryotherapy on oral mucosa: a study in healthy volunteers.

Svanberg A, Ohrn K, Broström H, Birgegård G. Svanberg A, et al. Among authors: birgegard g. Med Oncol. 2012 Dec;29(5):3587-91. doi: 10.1007/s12032-012-0230-z. Epub 2012 Apr 5. Med Oncol. 2012. PMID: 22476810

5

Oral cryotherapy reduces mucositis and improves nutrition - a randomised controlled trial.

Svanberg A, Ohrn K, Birgegård G. Svanberg A, et al. Among authors: birgegard g. J Clin Nurs. 2010 Aug;19(15-16):2146-51. doi: 10.1111/j.1365-2702.2010.03255.x. J Clin Nurs. 2010. PMID: 20659194 Clinical Trial.

6

Five-year follow-up of survival and relapse in patients who received cryotherapy during high-dose chemotherapy for stem cell transplantation shows no safety concerns.

Svanberg A, Ohrn K, Birgegård G. Svanberg A, et al. Among authors: birgegard g. Eur J Cancer Care (Engl). 2012 Nov;21(6):822-8. doi: 10.1111/ecc.12009. Epub 2012 Sep 11. Eur J Cancer Care (Engl). 2012. PMID: 22967016

7

Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation.

Birgegård G, Wide L, Simonsson B. Birgegård G, et al. Br J Haematol. 1989 Jul;72(3):462-6. doi: 10.1111/j.1365-2141.1989.tb07733.x. Br J Haematol. 1989. PMID: 2669930

8

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G; Nordic Study Group for Myeloproliferative Disorders. Samuelsson J, et al. Among authors: birgegard g. Cancer. 2006 Jun 1;106(11):2397-405. doi: 10.1002/cncr.21900. Cancer. 2006. PMID: 16639737 Clinical Trial.

9

Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test.

Goch J, Birgegård G, Danielson BG, Wikström B. Goch J, et al. Among authors: birgegard g. Nephron. 1996;73(3):403-6. doi: 10.1159/000189100. Nephron. 1996. PMID: 8832597 Clinical Trial.

10

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.

Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L, Brune M, LeBlanc K, Kutti J, Birgegård G; Swedish Group for Myeloproliferative Disorders. Merup M, et al. Among authors: birgegard g. Br J Haematol. 2006 Nov;135(3):367-73. doi: 10.1111/j.1365-2141.2006.06302.x. Epub 2006 Sep 14. Br J Haematol. 2006. PMID: 16972981

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results